ArticleThe Journal of urology2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Article in The Journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05698576 (TRANBERG® Transperineal MR/US Focalyx Fusion Laser--Induced Thermal Therapy in the Office Setting Under Local Anesthesia), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TRANBERG® Transperineal MR/US Focalyx Fusion Laser--Induced Thermal Therapy in the Office Setting Under Local Anesthesia
Who cites it
15 citing papers in PubMed.
- Clinicopathologic profile of Filipino men with low-risk prostate cancer and predictors of unfavorable pathology at radical prostatectomy.Prostate international · 2026Article
- Active Surveillance for Low- and Favourable Intermediate-Risk Prostate Cancer: A Single-Centre Cohort Study on Discontinuation Rates and Quality-of-Life Outcomes.Journal of personalized medicine · 2026Article
- Review
- Risk of reclassification and novel tools in active surveillance.Asian journal of urology · 2025Review
- Organ-confined prostate cancer with negative surgical margins in an entirely-embedded radical prostatectomy is essentially non-lethal-a retrospective single-institutional study of 520 patients.International urology and nephrology · 2025Article
- Active Surveillance for Taiwanese Men with Localized Prostate Cancer: Intermediate-Term Outcomes and Predictive Factors.The world journal of men's health · 2024Article
- Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study.Cancer medicine · 2024Article
- Review
- Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?Urologic oncology · 2023Article
- Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Increasing aggressive prostate cancer.The Canadian journal of urology · 2022Article
- Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.Cancers · 2022Review
- To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.JAMA oncology · 2022Article
- Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG advances · 2022Article
- Leveraging MRI to reduce overtreatment in low‑grade prostate cancer: a retrospective single‑centre cohort study.Therapeutic advances in urologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
23 authors.
Funding
Abstract
purposeWe examined the demographic and clinicopathological parameters associated with the time to convert from active surveillance to treatment among men with prostate cancer. MATERIALS AND
methodsA multi-institutional cohort of 7,279 patients managed with active surveillance had data and biospecimens collected for germline genetic analyses.
resultsOf 6,775 men included in the analysis, 2,260 (33.4%) converted to treatment at a median followup of 6.7 years. Earlier conversion was associated with higher Gleason grade groups (GG2 vs GG1 adjusted hazard ratio [aHR] 1.57, 95% CI 1.36-1.82; ≥GG3 vs GG1 aHR 1.77, 95% CI 1.29-2.43), serum prostate specific antigen concentrations (aHR per 5 ng/ml increment 1.18, 95% CI 1.11-1.25), tumor stages (cT2 vs cT1 aHR 1.58, 95% CI 1.41-1.77; ≥cT3 vs cT1 aHR 4.36, 95% CI 3.19-5.96) and number of cancerous biopsy cores (3 vs 1-2 cores aHR 1.59, 95% CI 1.37-1.84; ≥4 vs 1-2 cores aHR 3.29, 95% CI 2.94-3.69), and younger age (age continuous per 5-year increase aHR 0.96, 95% CI 0.93-0.99). Patients with high-volume GG1 tumors had a shorter interval to conversion than those with low-volume GG1 tumors and behaved like the higher-risk patients. We found no significant association between the time to conversion and self-reported race or genetic ancestry.
conclusionsA shorter time to conversion from active surveillance to treatment was associated with higher-risk clinicopathological tumor features. Furthermore, patients with high-volume GG1 tumors behaved similarly to those with intermediate and high-risk tumors. An exploratory analysis of self-reported race and genetic ancestry revealed no association with the time to conversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.